Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson TA, Simmons BH, Lippincott J, Casperson GF, Levin WJ, Stampino CG, Shalinsky DR, Ferrara KW, Fiedler W, Bertolini F. Hu-Lowe DD, et al. Among authors: stampino cg. Cancer Res. 2011 Feb 15;71(4):1362-73. doi: 10.1158/0008-5472.CAN-10-1451. Epub 2011 Jan 6. Cancer Res. 2011. PMID: 21212415 Free PMC article.
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.
Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. Goff LW, et al. Among authors: stampino cg. Clin Cancer Res. 2016 May 1;22(9):2146-54. doi: 10.1158/1078-0432.CCR-15-1622. Epub 2015 Dec 11. Clin Cancer Res. 2016. PMID: 26655846 Free PMC article. Clinical Trial.
Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, Goumans MJ, ten Dijke P. van Meeteren LA, et al. Among authors: stampino cg. J Biol Chem. 2012 May 25;287(22):18551-61. doi: 10.1074/jbc.M111.338103. Epub 2012 Apr 5. J Biol Chem. 2012. PMID: 22493445 Free PMC article.
Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer.
Bajetta E, Biganzoli L, Carnaghi C, Di Bartolomeo M, Spagnoli I, Cassata A, Galante E, Mariani L, Stampino CG, Buzzoni R. Bajetta E, et al. Among authors: stampino cg. Cancer. 1998 Sep 15;83(6):1136-41. doi: 10.1002/(sici)1097-0142(19980915)83:6<1136::aid-cncr12>3.0.co;2-6. Cancer. 1998. PMID: 9740078 Clinical Trial.
Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma.
Bajetta E, Di Bartolomeo M, Somma L, Moreschi M, Comella G, Turci D, Gebbia V, Scanni A, Bordogna G, Stampino CG. Bajetta E, et al. Among authors: stampino cg. Cancer. 1996 Nov 15;78(10):2087-93. doi: 10.1002/(sici)1097-0142(19961115)78:10<2087::aid-cncr8>3.0.co;2-l. Cancer. 1996. PMID: 8918401 Clinical Trial.
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.
Lencioni M, Falcone A, Allegrini G, Pfanner E, Masi G, Brunetti I, Di Marsico R, Fontana E, Orlandini C, Stampino CG, Bartolozzi C, Conte PF. Lencioni M, et al. Among authors: stampino cg. Oncology. 2000 Sep;59(3):204-9. doi: 10.1159/000012162. Oncology. 2000. PMID: 11053987 Clinical Trial.
19 results